{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:31Z","timestamp":1790383831663,"version":"4.1.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"DOI":"10.1093\/jacamr\/dlae003","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T11:35:09Z","timestamp":1705923309000},"source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment of MSSA acute bacterial prostatitis using dalbavancin"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-6123","authenticated-orcid":false,"given":"Athena L V","family":"Hobbs","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Cardinal Health Innovative Delivery Solutions , 7000 Cardinal Place , Dublin, OH 43017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Gelfand","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, College of Medicine, Memphis , 910 Madison Ave, Ste 1031 , Memphis, TN 38163, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Marjoncu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Methodist Le Bonheur Healthcare , 1265 Union Ave , Memphis, TN 38104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"2024022909280756600_dlae003-B1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1086\/652861","article-title":"Treatment of bacterial prostatitis","volume":"50","author":"Lipsky","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024022909280756600_dlae003-B2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0002-9343(76)90372-7","article-title":"Metastatic infection secondary to genitourinary tract sepsis","volume":"61","author":"Siroky","year":"1976","journal-title":"Am J Med"},{"key":"2024022909280756600_dlae003-B3","author":"Bonkat"},{"key":"2024022909280756600_dlae003-B4","doi-asserted-by":"crossref","first-page":"ofaa293","DOI":"10.1093\/ofid\/ofaa293","article-title":"Use of a standardized dalbavancin approach to facility earlier hospital discharge for vulnerable patients receiving prolonged inpatient antibiotic therapy","volume":"7","author":"Vazquez Deida","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2024022909280756600_dlae003-B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12941-015-0081-5","article-title":"Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies","volume":"14","author":"Dunne","year":"2015","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2024022909280756600_dlae003-B6","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10096-022-04437-0","article-title":"Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018\u20132020)","volume":"41","author":"Sader","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024022909280756600_dlae003-B7","doi-asserted-by":"crossref","first-page":"ofz372","DOI":"10.1093\/ofid\/ofz372","article-title":"Clinical characteristics and outcome of Staphylococcus aureus prostate abscess, ten-year experience at a tertiary care center","volume":"6","author":"Walker","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024022909280756600_dlae003-B8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/antibiotics10111296","article-title":"Comparative analysis of dalbavancin versus other antimicrobial options for Gram-positive cocci infections: effectiveness, hospital stay and mortality","volume":"10","author":"de Pablo-Mir\u00f3","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2024022909280756600_dlae003-B9","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024022909280756600_dlae003-B10","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2024022909280756600_dlae003-B11","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/antibiotics9100700","article-title":"Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care","volume":"9","author":"Ajaka","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2024022909280756600_dlae003-B12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","article-title":"Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial","volume":"23","author":"Turner","year":"2022","journal-title":"Trials"},{"key":"2024022909280756600_dlae003-B13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in health volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2024022909280756600_dlae003-B14","author":"Allergan USA"},{"key":"2024022909280756600_dlae003-B15","author":"Janssen Pharmaceuticals Inc"},{"issue":"Suppl 1","key":"2024022909280756600_dlae003-B16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0213-005X(17)30031-9","article-title":"[Dalbavancin: pharmacokinetic and pharmacodynamic parameters]","volume":"35","author":"Azanza","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2024022909280756600_dlae003-B17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0022-5347(17)57333-4","article-title":"The pH of prostatic fluid: a reappraisal and therapeutic implications","volume":"120","author":"Fair","year":"1978","journal-title":"J Urol"},{"key":"2024022909280756600_dlae003-B18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/art.1780090106","article-title":"Measurement of synovial fluid pH in normal and arthritic knees","volume":"9","author":"Cummings","year":"1966","journal-title":"Arthritis Rheum"},{"key":"2024022909280756600_dlae003-B19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/dkf058","article-title":"Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium","volume":"50","author":"Mercier","year":"2002","journal-title":"J Antimicrob Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/1\/dlae003\/56756017\/dlae003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/1\/dlae003\/56756017\/dlae003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:28:35Z","timestamp":1709198915000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlae003\/7582864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlae003","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,12,28]]},"article-number":"dlae003"}}